Search results
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 3 hours agoThis week, an FDA advisory committee unanimously recommended approval of Eli Lilly’s LLY Alzheimer's...
Is It Too Late to Buy Pfizer Stock?
The Motley Fool via AOL· 4 hours agoAre Pfizer's (NYSE: PFE) best days behind it? If the stock's critics are to be believed, the answer is an emphatic "yes, obviously," with issues like its...
Childress Capital Advisors LLC Has $583,000 Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 5 hours agoChildress Capital Advisors LLC boosted its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 2.2% during the 4th quarter, according to its most recent 13F filing with the Securities ...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 23 hours agoPfizer disclosed on May 7 that a child participating in another...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 1 day agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 2 days agoSome say the art of investing is the ability of catching falling knives. Pfizer Inc. (NYSE:PFE) shares have sold off in 2023 and represent an attractive...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 2 days agoDespite a bevy of promising updates for its cancer treatments, Pfizer stock remains trapped below a...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 20 hours agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer faces setback with gene therapy acquired from North Carolina firm - Triangle Business Journal
The Business Journals· 21 hours agoPfizer is facing a major clinical setback in a gene therapy program with ties to the Triangle. The...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 1 day agogained 4% premarket on Thursday after a potential competitor to its gene therapy stumbled in a...